Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 1
2018 4
2019 4
2020 3
2022 3
2023 3
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Targeting MYC in combination with epigenetic regulators induces synergistic anti-leukemic effects in MLLr leukemia and simultaneously improves immunity.
Fitzel R, Secker-Grob KA, Keppeler H, Korkmaz F, Schairer R, Erkner E, Schneidawind D, Lengerke C, Hentrich T, Schulze-Hentrich JM, Schneidawind C. Fitzel R, et al. Among authors: schneidawind c. Neoplasia. 2023 Jul;41:100902. doi: 10.1016/j.neo.2023.100902. Epub 2023 May 4. Neoplasia. 2023. PMID: 37148657 Free PMC article.
PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity.
Moraes Ribeiro E, Secker KA, Nitulescu AM, Schairer R, Keppeler H, Wesle A, Schmid H, Schmitt A, Neuber B, Chmiest D, Podavini S, Märklin M, Klimovich B, Schmitt M, Korkmaz F, Lengerke C, Schneidawind C, Schneidawind D. Moraes Ribeiro E, et al. Among authors: schneidawind c. J Immunother Cancer. 2024 Jan 31;12(1):e007829. doi: 10.1136/jitc-2023-007829. J Immunother Cancer. 2024. PMID: 38296597 Free PMC article.
Inhibition of effector B cells by ibrutinib in systemic sclerosis.
Einhaus J, Pecher AC, Asteriti E, Schmid H, Secker KA, Duerr-Stoerzer S, Keppeler H, Klein R, Schneidawind C, Henes J, Schneidawind D. Einhaus J, et al. Among authors: schneidawind c. Arthritis Res Ther. 2020 Mar 30;22(1):66. doi: 10.1186/s13075-020-02153-8. Arthritis Res Ther. 2020. PMID: 32228672 Free PMC article.
Low Graft Invariant Natural Killer T-Cell Dose Is a Risk Factor for Cytomegalovirus Reactivation After Allogeneic Hematopoietic Cell Transplantation.
Schneidawind D, Duerr-Stoerzer S, Liewer S, Renner S, Sánchez Navarro B, Atar D, Keppeler H, Beck R, Hamprecht K, Kanz L, Lengerke C, Schneidawind C. Schneidawind D, et al. Among authors: schneidawind c. Transplant Cell Ther. 2022 Aug;28(8):513.e1-513.e4. doi: 10.1016/j.jtct.2022.05.011. Epub 2022 May 14. Transplant Cell Ther. 2022. PMID: 35580734 Free article.
MAT2A as Key Regulator and Therapeutic Target in MLLr Leukemogenesis.
Secker KA, Bloechl B, Keppeler H, Duerr-Stoerzer S, Schmid H, Schneidawind D, Jeong J, Hentrich T, Schulze-Hentrich JM, Schneidawind C. Secker KA, et al. Among authors: schneidawind c. Cancers (Basel). 2020 May 24;12(5):1342. doi: 10.3390/cancers12051342. Cancers (Basel). 2020. PMID: 32456310 Free PMC article.
Invariant natural killer T cells are functionally impaired in patients with systemic sclerosis.
Pecher AC, Kettemann F, Asteriti E, Schmid H, Duerr-Stoerzer S, Keppeler H, Henes JC, Klein R, Hinterleitner C, Secker KA, Schneidawind C, Kanz L, Schneidawind D. Pecher AC, et al. Among authors: schneidawind c. Arthritis Res Ther. 2019 Oct 15;21(1):212. doi: 10.1186/s13075-019-1991-y. Arthritis Res Ther. 2019. PMID: 31615552 Free PMC article.
21 results